The Postdoctoral Training Award supports prostate cancer research training opportunities for recent doctoral graduates. These awards primarily provide salary support for the Principal Investigator (PI); the postdoctoral trainee is considered the PI of the application. The PI must exhibit strong potential for, and commitment to, pursuing a career as an investigator at the forefront of prostate cancer research; however, the PI is not required to have previous prostate cancer research experience. Applications must include at least one mentor, appropriate to the proposed training and research project, who has experience in prostate cancer research and training as demonstrated by a record of active funding, recent publications, and successful mentorship. The selected mentor(s) should demonstrate a clear commitment to the PI's training and be well qualified to contribute significantly to the development of the PI toward independence as a prostate cancer researcher.
The mission of the FY14 PCRP is to find and fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of men experiencing the impact of the disease. Specifically, the PCRP seeks to promote highly innovative, groundbreaking research; high-impact research with near-term clinical relevance; multidisciplinary, synergistic research; translational studies to support the fluid transfer of knowledge between bedside and bench; research on patient survivorship and quality of life; the next generation of prostate cancer investigators through mentored research; and research on disparities in the incidence and mortality of prostate cancer.
Consistent with the program's mission to eliminate death from prostate cancer and enhance the well-being of men experiencing the impact of the disease, including those from disproportionately affected populations, each PCRP funding opportunity either requires or encourages applications to address one of the following four PCRP overarching challenges:
- Develop better tools for early detection of clinically relevant disease
- Distinguish aggressive from indolent disease in men newly diagnosed with prostate cancer
- Develop effective treatments and address mechanisms of resistance for men with high risk or metastatic prostate cancer
- Develop strategies to optimize the physical and mental health of men with prostate cancer
All applications for the FY14 PCRP funding opportunities are also expected to address at least one of the following PCRP focus areas:
- Biomarker Development: Validation and qualification of biomarkers for early detection of clinically relevant disease or for prognosis or prediction and assessment of response to therapies
- Genetics: Understanding host or tumor genetics and epigenetics responsible for susceptibility, disease progression, and treatment outcomes for clinically relevant prostate cancer
- Imaging: Development of new anatomic, functional, and molecular imaging approaches for the detection and management of clinically relevant prostate cancer
- Mechanisms of Resistance: Understanding primary and acquired resistance to therapy
- Survivorship and Palliative Care: Improving the quality of life and well-being of prostate cancer patients and their families
- Therapy: Identification of new targets, pathways, and therapeutic modalities
- Tumor and Microenvironment Biology: Understanding the intrinsic and extrinsic mechanisms contributing to tumor development and the progression of prostate cancer.
For more information, please visit: